The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is:
Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer?
Participants will be randomised to receive either trilaciclib or placebo.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Confirmed diagnosis of Limited-Stage Small Cell Lung Cancer
* Complete recovery from prior anti-tumor surgical procedures
* Measurable and evaluable disease through tumor assessment
* Willingness to participate and sign informed consent form
Exclusion Criteria:
* Extensive Stage Small Cell Lung Cancer
* Active cardiovascular disease
* Known hypersensitivity to trilaciclib, etoposide, carboplatin, cisplatin or any component in their formulations
* Pregnant or nursing women
Primary outcome measure(s)
To Compare trilaciclib to placebo on prevention of myelosuppression — From enrollment and 4 months after Duration and occurrence of severe neutropenia
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.